Nuo Therapeutics, Inc. (OTC:AURX)
| Market Cap | $44.38M-60.1% |
| Revenue (ttm) | $6.03M+131.1% |
| Net Income | -$1.90M+21.8% |
| EPS | -$0.04+24.0% |
| Shares Out | 48.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,100 |
| Open | $1.05 |
| Previous Close | $1.07 |
| Day's Range | $0.91 - $1.05 |
| 52-Week Range | $0.77 - $2.29 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | $3.00(+228.41%) |
| Earnings Date | Mar 3, 2027 |
About AURX
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Nuo Therapeutics, Inc. Stock Analysis — InsiderScore
Nuo Therapeutics, Inc. scored higher than 30% of companies evaluated by InsiderBuying, and ranked 60th out of 102 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Nuo Therapeutics, Inc. bought $9.5K of stock across 2 purchases in the last 90 days, the largest of them $8.7K.
The average purchase added about 0% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 3, 2027Earnings report
$AURX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AURX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AURX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AURX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AURX Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AURX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AURX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from AURX’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-2.0 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
